Becton, Dickinson and Company (BDX) Stock

Becton, Dickinson and Company (BDX) is a Healthcare stock trading at $150.85 (as of 2026-07-09), with a market capitalization of $41.57B and a trailing P/E of 36.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Becton, Dickinson and Company develops and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare providers, clinical laboratories, life science researchers, the pharmaceutical industry, and other customers worldwide. Its offerings span medical technologies and laboratory and diagnostic solutions, including products for injections, infusion and specimen collection, and related testing and workflow needs.

Understand Becton, Dickinson and Company: how it makes money

Becton, Dickinson and Company (BD) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, and it makes money from product sales across these end markets.

BD’s profit model is driven by selling a wide portfolio of medical and laboratory products into multiple customer types, including healthcare institutions, clinicians, researchers, clinical laboratories, and pharma.

Revenue by segment (latest quarter)
MDS	$2.1B
MMS	$1.4B
PS	$1.1B
COVIDDx	$0.0B

Business quality (Weak): Business description and segment-style revenue inputs are available (MDS, MMS, PS, COVID-19 Dx), but the provided segment revenue figures do not naturally sum to the reported total without normalization, so segment read-through should be treated as approximate.

Valuation: At 37× earnings, BDX trades 14% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

Multi-end-market product demand: BD sells medical supplies and devices into several end markets (healthcare institutions, physicians, life science researchers, clinical laboratories, pharma, and the general public), which can spread dependence across customer types.
Large, diversified product mix by category: The company’s described portfolio includes peripheral IV and catheters, central lines, dialysis catheters, vascular care, needle-free IV connectors, closed-system drug transfer devices, and hazardous drug detections, which supports multiple product lines.

Bear case

Segment performance drives results: Operating outcomes are closely tied to how the company’s major product segment revenues (MDS, MMS, and PS) perform.
COVID-19 Dx is a smaller contributor in the provided data: COVID-19 Dx revenue is listed as 16.0 (versus much larger MDS, MMS, and PS inputs), so overall swings from this category alone are likely limited based on the provided figures.

Valuation — source: SEC EDGAR (first-party)
Price	$150.85
Market Cap	$41.57B
P/E Ratio	36.5
EV / EBITDA	9.0
Price / Book	1.72
Price / Sales	1.95
FCF Yield	1.3%
DCF Value (model)	$3.49
DCF Upside vs Price	-97.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$21.84B
Net Margin	7.7%
Revenue Growth (YoY)	-10.6%
EPS Growth (YoY)	-203.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.85 (grey)

Valuation vs Sector & Industry
Stock P/E	36.5
Sector P/E (Healthcare)	21.7
Industry P/E (Medical Equipment)	29.8
vs Sector	68.5%
vs Industry	22.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($7.12B)
Institutional Holders Tracked	10
Congressional Trades (recent)	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Thomas E. Polen Jr.
Employees	70,000
Country	US
IPO Date	1973-02-21

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-07-09.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.